
WHAT IS CLAIMED:

1. A compound, wherein the anionic form of the compound has the following formula (SEQ ID NO: 1089):



or a pharmaceutically acceptable salt thereof.

2. A modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide is 16 linked nucleosides in length and has the nucleobase sequence of SEQ ID NO: 1089, wherein the modified oligonucleotide comprises:


a gap segment consisting of ten linked deoxynucleosides;

a 5’ wing segment consisting of three linked nucleosides; and


a 3’ wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside

linkage is a phosphorothioate linkage; wherein each cytosine is a 5-methylcytosine; and wherein the conjugate group is positioned at the 5'end of the modified oligonucleotide and is



3. A compound, wherein the anionic form of the compound has the following formula (SEQ ID NO: 1089):



or a pharmaceutically acceptable salt thereof.

4. A modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide is 16 linked nucleosides in length and has the nucleobase sequence of SEQ ID NO: 1089, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a cEt sugar; wherein at least one internucleoside linkage is a phosphorothioate linkage; wherein each cytosine is a 5-methylcytosine.

5. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide is 16 linked nucleosides in length and has the nucleobase sequence of SEQ ID NO: 1089, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage is a phosphorothioate linkage; wherein each cytosine is a 5-methylcytosine.

6. A modified oligonucleotide, wherein the modified oligonucleotide consists of 16 linked nucleosides and has the nucleobase sequence consisting of SEQ ID NO: 1089, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage is a phosphorothioate linkage; wherein each cytosine is a 5-methylcytosine.

7. The compound or modified oligonucleotide of claims 1-3, wherein the pharmaceutically acceptable salt is a sodium salt.

8. The compound or modified oligonucleotide of claims 1-3, wherein the pharmaceutically acceptable salt is a potassium salt.

9. A composition comprising the compound or modified oligonucleotide of 1-6 and a pharmaceutically acceptable carrier.